Chronic Obstructive Pulmonary Disease | Unmet Need | Severe | US/EU |2021

The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs compete for a share of the maintenance space. Unfortunately, none of these agents can reverse the disease’s progression or repair lung tissue; instead, these treatments focus on improving breathing and reducing inflammation. Although inhaled medications are effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Thus, significant unmet need remains for more-effective therapies, especially for those patients whose symptoms are not adequately controlled with available therapies.

QUESTIONS ANSWERED

• What are the key drivers and goals of treatment of severe to very severe COPD? How do current therapies such as Boehringer Ingelheim’s Spiriva, GlaxoSmithKline’s Anoro and Trelegy, and AstraZeneca’s Symbicort perform on these measures?
• What drug attributes are key influencers on pulmonologists’ prescribing decisions, which have limited impact, and which are hidden opportunities?
• What are the prevailing areas of unmet need and opportunity in the treatment of severe to very severe COPD?
• What trade-offs across different clinical / nonclinical attributes and prices are acceptable to U.S. and European pulmonologists for a hypothetical new COPD drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European pulmonologists fielded in February 2021

Key companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline

Key drugs: Advair / Seretide, Anoro, Spiriva, Stiolto / Spiolto, Symbicort, Trelegy, Yupelri